PF-03715455

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
PF-03715455
DrugBank Accession Number
DB12138
Background

PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive, and Chronic Obstructive Pulmonary Disease (COPD).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 700.273
Monoisotopic: 699.185307076
Chemical Formula
C35H34ClN7O3S2
Synonyms
Not Available
External IDs
  • PF-03715455

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Pyrazoles
Direct Parent
Phenylpyrazoles
Alternative Parents
Diarylthioethers / Phenyl-1,2,4-triazoles / Triazolopyridines / Thiophenol ethers / O-chlorophenols / 1-hydroxy-2-unsubstituted benzenoids / Alkylarylthioethers / Chlorobenzenes / Aryl chlorides / Pyridines and derivatives
show 10 more
Substituents
1,2,4-triazole / 1-hydroxy-2-unsubstituted benzenoid / 2-chlorophenol / 2-halophenol / Alcohol / Alkylarylthioether / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Aryl thioether
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
0TJ631J0KP
CAS number
1056164-52-3
InChI Key
VGEXRDWWPSGZDH-UHFFFAOYSA-N
InChI
InChI=1S/C35H34ClN7O3S2/c1-35(2,3)30-19-32(43(41-30)23-12-14-27(45)26(36)18-23)38-34(46)37-20-22-8-4-6-10-28(22)48-24-13-15-31-39-40-33(42(31)21-24)25-9-5-7-11-29(25)47-17-16-44/h4-15,18-19,21,44-45H,16-17,20H2,1-3H3,(H2,37,38,46)
IUPAC Name
3-[3-tert-butyl-1-(3-chloro-4-hydroxyphenyl)-1H-pyrazol-5-yl]-1-({2-[(3-{2-[(2-hydroxyethyl)sulfanyl]phenyl}-[1,2,4]triazolo[4,3-a]pyridin-6-yl)sulfanyl]phenyl}methyl)urea
SMILES
CC(C)(C)C1=NN(C(NC(=O)NCC2=CC=CC=C2SC2=CN3C(C=C2)=NN=C3C2=CC=CC=C2SCCO)=C1)C1=CC=C(O)C(Cl)=C1

References

General References
Not Available
PubChem Compound
11714580
PubChem Substance
347828435
ChemSpider
9889301
BindingDB
50361467
ChEMBL
CHEMBL1938400
PDBe Ligand
YIS
PDB Entries
2yis

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentAsthma1
2TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
1CompletedNot AvailableHealthy Volunteers (HV)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP6.95Chemaxon
pKa (Strongest Acidic)8.46Chemaxon
pKa (Strongest Basic)2.14Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area129.6 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity208.94 m3·mol-1Chemaxon
Polarizability72.53 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0ue9-3012019000-cac5e60ea2ade6a49387
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0000002900-c45597300391760e28c7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-1010009100-3a4518cf5e83723ca749
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0imi-0051049000-7bd75d6033a2517cb75d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00ed-0152039100-7fd3302377d5d0a5387c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001j-5241009000-a123e63e22de00bec309
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-239.3785
predicted
DeepCCS 1.0 (2019)
[M+H]+241.20338
predicted
DeepCCS 1.0 (2019)
[M+Na]+246.87619
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:26 / Updated at June 12, 2020 16:53